NCT03348930View on ClinicalTrials.gov

Tolcapone in Obsessive Compulsive Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 20, 2018

Primary Completion Date

December 14, 2020

Study Completion Date

December 14, 2020

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

Tolcapone 200 MG

All eligible study subjects will go through a 2-week treatment phase during which they will begin tolcapone at 100mg twice a day.

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT03348930 - Tolcapone in Obsessive Compulsive Disorder | Biotech Hunter | Biotech Hunter